Log in or Sign up for Free to view tailored content for your specialty!
Alzheimer’s Disease/Dementia News
Increased inflammation in early adulthood may predict worsening cognition in midlife
Persistent higher or moderate-to-increasing inflammation that begins in early adulthood may result in worsening midlife executive function and processing speed, according to data published in Neurology.
FDA approves injectable Kisunla for early symptomatic Alzheimer’s disease
The FDA approved Kisunla for adults with early symptomatic Alzheimer’s disease, including those with mild cognitive impairment and mild dementia with confirmed amyloid pathology.
Log in or Sign up for Free to view tailored content for your specialty!
Q&A: SAGE test catches cognitive impairment early in a ‘critical time’
A self-administered assessment tool was effective in identifying cognitive impairment vs. routine care in primary care settings, according to results recently published in Frontiers in Medicine.
Buntanetap linked to improved cognition, tau reduction in phase 2/3 study
In a phase 2/3 clinical trial, treatment with buntanetap was linked to cognitive gains as well as tau reduction at 12 weeks in those exhibiting mild to moderate symptoms of Alzheimer’s disease, according to the drug’s manufacturer.
FDA advisory committee backs donanemab for early-stage Alzheimer’s
An FDA advisory panel on Monday voted in favor of donanemab as a treatment for early symptomatic Alzheimer’s disease.
Cognitive outcomes improved with endovascular therapy in acute ischemic stroke
Endovascular therapy was linked with improved outcomes across five cognitive tests in those with acute ischemic stroke, according to research published in Neurology.
ADDF invests $5 million with Coya Therapeutics to develop, advance Alzheimer’s drugs
The Alzheimer’s Drug Discovery Foundation has invested $5 million in Coya Therapeutics to help accelerate development and advance drugs to prevent, treat and cure Alzheimer’s disease and related dementias.
Preeclampsia may drive risk for young-onset dementia
Women diagnosed with preeclampsia were 2.6 times more likely to develop early-onset dementia during 9 years of follow-up compared with women who did not have a hypertensive disorder of pregnancy, according to registry data.
Otsuka terminates development of treatment for agitation due to Alzheimer’s disease
Otsuka Pharmaceutical has terminated its development of AVP-786, a novel compound that was being researched as a potential treatment for patients with agitation due to Alzheimer’s disease, according to a company-issued press release.
Long-term extension studies seek to further evaluate ALZ-801 for Alzheimer’s disease
Alzheon Inc. has enrolled patients who completed either phase 2 or phase 3 trials to evaluate ALZ-801 as a treatment for early Alzheimer’s disease in long-term study extensions, according to a company-issued press release.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read